drug · antibody
SKYRIZI
updated 6mo ago/ RIS-ən-KIZ-uu-mab /
by $ABBV AbbVie Inc.🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 3Antibody drug with a maximum clinical stage of Approval (across all indications), with 7 approved and 6 investigational indications.
targets
Interleukin-23
all catalysts(0)
nothing on the calendar yet
Trials studying SKYRIZI
News(10)
- J&J and Protagonist’s Icotyde improves psoriatic arthritis but AbbVie’s Skyrizi likely to reignA Phase 3 trial showed that Johnson & Johnson and Protagonist Therapeutics’ oral therapy Icotyde improved psoriatic arthritis symptoms but AbbVie’s injectable is likely to hold court based on highe…biospace · 9d ago
- AbbVie bets up to $1.47B for Nxera’s discarded IBD programAbbVie’s $100 million upfront cash payment will purchase global rights to Nxera’s deprioritized oral small molecule, which has already completed Phase 1 testing.biospace · 14d ago
- AbbVie pens $1.4B deal for deprioritized IBD drug from NxeraAbbVie has added another angle to its relationship with Nxera, with the Big Pharma paying $100 million upfront for a phase 1 inflammatory bowel disease candidate.fiercebiotech · 15d ago
- AbbVie’s Q3 beat should keep ‘train rolling’ as company eyes bolt-on dealsStrong immunology and neuroscience sales fueled AbbVie’s latest quarterly beat as the pharma’s stock continues to hit all-time highs.biospace · 19d ago
- Another autoimmune CAR-T death; Treasury zeroes in on China dealsA patient who received Bristol Myers’ zola-cel died 44 days later. Elsewhere, Gilead paid nearly $1.3 billion for a potential threat to J&J’s newly approved psoriasis pill.biopharma_dive · 23d ago
- As AbbVie’s Crohn’s combo beats Skyrizi in mid-stage test, analysts laud autoimmune visionAbbVie’s next-gen dual-targeting therapy elicited higher rates of remission than its IL-23 inhibitor Skyrizi in a Phase 2a trial of Crohn’s disease, leading analysts to wonder if the blockbuster ca…biospace · 1mo ago
- AbbVie’s Skyrizi combo beats Skyrizi alone in mid-stage Crohn’s trialAbbVie’s Skyrizi-based combination therapy for inflammatory bowel disease worked better than Skyrizi alone in a mid-stage trial in Crohn’s disease, the company said Monday. The new product is coden…endpoints · 1mo ago
- AbbVie’s next-gen Crohn’s disease combo beats Skyrizi in phase 2 trialAbbVie’s next-generation Crohn’s disease combination candidate has beaten Skyrizi in a midphase clinical trial.fiercebiotech · 1mo ago
- Biotech builder Paragon imports Apogee's top brass after AbbVie buyoutIt’s been a busy morning for Paragon Labs. In addition to bringing over much of the leadership team from AbbVie-acquired Apogee Therapeutics, Paragon has overseen a reverse merger to take its hyper…fiercebiotech · 1mo ago
- Pharma’s $500B patent problem will come in waves — not as a cliffMerck is the most vulnerable to generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and others will also grapple with patent losses in the years to come.biopharma_dive · 1mo ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that